Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles. - Al-Jarshawi M; Cole A; Bagur R; Wang HY; Ng CH; Yu D; Chew NWS; Mamas MA (Cardiovascular diabetology. Endocrinology reports, 2026)